A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

NCT02735876 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: acalabrutinib
DRUG: ibrutinib
DRUG: rituximab

Sponsor

Acerta Pharma BV